Biblio
Alemtuzumab, dual GVHD prophylaxis, and lower CD3+ T cell doses equalize rates of acute and chronic GVHD among pediatric patients receiving allogeneic HSCT with matched unrelated donor PBSC or bone marrow grafts. Transplant Cell Ther. 2023.
. .
Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome. Biol Blood Marrow Transplant. 2020.
. Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency. J Allergy Clin Immunol. 2020.